Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. trimmed its holdings in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 9.7% in the fourth quarter, HoldingsChannel reports. The firm owned 14,657 shares of the biopharmaceutical company’s stock after selling 1,571 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Horizon Therapeutics Public were worth $1,668,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Horizon Therapeutics Public by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 21,276,662 shares of the biopharmaceutical company’s stock worth $1,316,812,000 after purchasing an additional 354,287 shares in the last quarter. BlackRock Inc. increased its stake in shares of Horizon Therapeutics Public by 7.0% during the 3rd quarter. BlackRock Inc. now owns 15,619,023 shares of the biopharmaceutical company’s stock worth $966,660,000 after purchasing an additional 1,020,576 shares in the last quarter. State Street Corp increased its stake in shares of Horizon Therapeutics Public by 3.4% during the 3rd quarter. State Street Corp now owns 5,732,387 shares of the biopharmaceutical company’s stock worth $354,777,000 after purchasing an additional 188,413 shares in the last quarter. Barclays PLC increased its stake in shares of Horizon Therapeutics Public by 1,235.5% during the 3rd quarter. Barclays PLC now owns 3,852,296 shares of the biopharmaceutical company’s stock worth $238,420,000 after purchasing an additional 3,563,851 shares in the last quarter. Finally, Pictet Asset Management SA increased its stake in shares of Horizon Therapeutics Public by 12.3% during the 3rd quarter. Pictet Asset Management SA now owns 2,509,590 shares of the biopharmaceutical company’s stock worth $155,319,000 after purchasing an additional 274,876 shares in the last quarter. 91.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HZNP has been the subject of a number of recent research reports. TheStreet cut shares of Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a research note on Monday, May 8th. StockNews.com assumed coverage on shares of Horizon Therapeutics Public in a research note on Saturday. They issued a “buy” rating for the company. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $111.42.

Horizon Therapeutics Public Stock Down 14.2 %

Shares of NASDAQ:HZNP opened at $96.34 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.89 and a current ratio of 4.07. The company has a market cap of $22.03 billion, a PE ratio of 60.59, a price-to-earnings-growth ratio of 4.23 and a beta of 1.13. Horizon Therapeutics Public Limited has a 52 week low of $57.84 and a 52 week high of $113.83. The firm has a 50 day simple moving average of $109.78 and a 200 day simple moving average of $104.60.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 EPS for the quarter, missing the consensus estimate of $1.17 by ($0.34). The firm had revenue of $832.10 million during the quarter, compared to analysts’ expectations of $897.06 million. Horizon Therapeutics Public had a net margin of 10.40% and a return on equity of 20.31%. The firm’s revenue was down 6.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 EPS. As a group, research analysts expect that Horizon Therapeutics Public Limited will post 5.31 earnings per share for the current year.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.